|
Back to Home » December 2022 News » China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy |
China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy |
December 30, 2022
STOCKHOLM, Dec. 30, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has recommended Priority Review for the...
Source URL: https://www.prnewswire.com:443/news-releases/china-cdenmpa-recommends-priority-review-for-nefecon-for-the-treatment-of-primary-iga-nephropathy-301711327.html
|
|
|
|
